Novavax Investor Relations https://ir.novavax.com/ Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial https://novavax.investorroom.com/2025-06-11-Novavaxs-COVID-19-Influenza-Combination-and-Stand-alone-Influenza-Vaccine-Candidates-Showed-Robust-Immune-Responses-and-Were-Well-Tolerated-in-Initial-Cohort-of-a-Phase-3-Trial <p>Both vaccine candidates induced robust immune responses across all antigens tested No new safety signals were observed and both vaccine candidates were well tolerated consistent with past trials...</p> 06/11/2025 https://novavax.investorroom.com/2025-06-11-Novavaxs-COVID-19-Influenza-Combination-and-Stand-alone-Influenza-Vaccine-Candidates-Showed-Robust-Immune-Responses-and-Were-Well-Tolerated-in-Initial-Cohort-of-a-Phase-3-Trial Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza https://novavax.investorroom.com/2024-12-10-Novavax-Initiates-Phase-3-Trial-for-COVID-19-Influenza-Combination-and-Stand-Alone-Influenza <p>Company continuing to work with the U.S. FDA on potential for accelerated approval pathway Novavax intends to partner on both candidates to advance to filing and commercialization GAITHERSBURG,...</p> 12/10/2024 https://novavax.investorroom.com/2024-12-10-Novavax-Initiates-Phase-3-Trial-for-COVID-19-Influenza-Combination-and-Stand-Alone-Influenza U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial https://novavax.investorroom.com/2024-11-11-U-S-FDA-Removes-Clinical-Hold-on-Novavaxs-COVID-19-Influenza-Combination-and-Stand-alone-Influenza-Phase-3-Trial <p>Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the...</p> 11/11/2024 https://novavax.investorroom.com/2024-11-11-U-S-FDA-Removes-Clinical-Hold-on-Novavaxs-COVID-19-Influenza-Combination-and-Stand-alone-Influenza-Phase-3-Trial Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023 https://novavax.investorroom.com/2023-10-11-Novavax-Advances-Science-Supporting-Protein-based-Vaccine-Technology-at-IDWeek-2023-and-World-Vaccine-Congress-Europe-2023 <p>Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023, October...</p> 10/11/2023 https://novavax.investorroom.com/2023-10-11-Novavax-Advances-Science-Supporting-Protein-based-Vaccine-Technology-at-IDWeek-2023-and-World-Vaccine-Congress-Europe-2023 Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses https://novavax.investorroom.com/2023-05-09-Positive-Phase-2-Topline-Results-Show-Novavaxs-COVID-Influenza-Combination,-Stand-alone-Influenza-and-High-dose-COVID-Vaccine-Candidates-Demonstrate-Robust-Immune-Responses <p>This Phase 2 trial is evaluating three vaccine candidates: COVID-Influenza Combination, stand-alone influenza and high-dose COVID Preliminary topline immune responses for all three vaccine...</p> 05/09/2023 https://novavax.investorroom.com/2023-05-09-Positive-Phase-2-Topline-Results-Show-Novavaxs-COVID-Influenza-Combination,-Stand-alone-Influenza-and-High-dose-COVID-Vaccine-Candidates-Demonstrate-Robust-Immune-Responses